Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

Willow Biosciences Inc T.WLLW

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.

    Latest News

    WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND...


    WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC


    WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD...


    WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST...


    WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE...


    WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023


    WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO...


    WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE


    WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING


    WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API...


    WILLOW BIOSCIENCES ANNOUNCES COMPANY INSIDER LED CONVERTIBLE DEBENTURE FINANCING


    WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED...


    WILLOW ANNOUNCES FILING OF PATENT APPLICATION FOR PROCESS TO PRODUCE CORTICOSTEROIDS AT...


    WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM


    WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP...